If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 151 - 160 of 304
Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)
Objective
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)
Protocol No
PULM-CFF-STOP360AG
Categories
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Protocol No
CORCEPT-CORT125134-557-BELLA
Categories
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Objective
Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Protocol No
EXACT-EXACTDNA-003-NSABP-B-64
Categories
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-Directed Antibody-Drug Conjugate, in Subjects with Platinum-Resistant, High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Objective
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer. This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer.
Protocol No
GOG-3096-DAIICHI-DS6000-109
Categories
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY Study)
Objective
The AIRTIVITY Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Protocol No
PULM-BOEHRINGER-AIRTIVITY
Categories
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery
Objective
Testing the addition of chemotherapy or chemo-immunotherapy to the usual surgery for advanced head and neck cancer
Protocol No
NRG-HN015-NEOPOLIS
Categories
A First-in-Human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients with Locally Advanced Un-Resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Objective
Safety, PK and efficacy of QXL138AM in patients with solid tumors and multiple myeloma
Protocol No
NAMMI-QXL138AM-001
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE)
Objective
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (TRANSPIRE)
Protocol No
SURG-BIOGEN-TRANSPIRE-MVI
Categories
Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion
Objective
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Protocol No
NRG-GI012-HELIO-RT
Categories
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy (PREVENT)
Objective
Prevention of Recurrence of C. Difficile Colitis With UCDA as a Supplement to Standard Therapy
Protocol No
GI-IIT-STEIN-PREVENT
Categories